BioPharmX Corporation Announces Proposed Public Offering of Common Stock and Warrants
MENLO PARK, Calif., March 28, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The common stock and warrants are being offered under the company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). BioPharmX intends to use the net proceeds of the offering for general corporate purposes, which may include funding research and development, increasing working capital, and acquisitions or investments in businesses, products, or technologies that are complementary to its own.
Maxim Group LLC is acting as lead book-running manager and CRT Capital Group LLC is acting as co-book-running manager for the offering. Rodman & Renshaw, a unit of H.C Wainwright & Co., LLC, is acting as co-manager for the offering.
The common stock and warrants are being offered by means of a prospectus supplement and accompanying prospectus, forming a part of the effective registration statement, a copy of which may be obtained, when available, at the website of the SEC at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement and accompanying prospectus also may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (212) 895-3745.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
MENLO PARK, Calif., March 28, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The common stock and warrants are being offered under the company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). BioPharmX intends to use the net proceeds of the offering for general corporate purposes, which may include funding research and development, increasing working capital, and acquisitions or investments in businesses, products, or technologies that are complementary to its own.
Maxim Group LLC is acting as lead book-running manager and CRT Capital Group LLC is acting as co-book-running manager for the offering. Rodman & Renshaw, a unit of H.C Wainwright & Co., LLC, is acting as co-manager for the offering.
The common stock and warrants are being offered by means of a prospectus supplement and accompanying prospectus, forming a part of the effective registration statement, a copy of which may be obtained, when available, at the website of the SEC at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement and accompanying prospectus also may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at (212) 895-3745.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
